In the hypercholesterolemic urinary bladder cancer (UBC) mouse model, ezetimibe significantly suppress HFHC-induced serum lipid (TC, LDL-C, and ox-LDL), and decrease the percentage of cancer cells (CK5+, CK14+, and p-STAT3+) and cancer stemness markers (ALDH1A1, CD44, KLF4, and Nanog) [1]. Here, KRT14 is linked to cancer.